

**In the Claims:**

Please cancel claims 10, 15, 17, 88, 93 and 96 without prejudice.

Claims 1, 13, 87, 89, 90 and 94 were amended but were not entered. See Response dated October 27, 2003. Applicants respectfully request that claims presented here that are identified as "Not entered" be examined on their merits. Further, for Examiner's convenience in examining the "Not entered" claims presented here, Applicants enclosed herewith a copy of the Response filed on October 27, 2003, showing the amended claims corresponding to the claims presented here as "Not entered" claims.

1. (Not entered)

2-3. (Cancelled).

4. (Previously presented) The composition of claim 1 wherein said oligonucleotide is a ribozyme or a peptide nucleic acid.

5. (Original) The composition of claim 1 wherein said emulsion is selected from the group consisting of an oil-in-water emulsion, a water-in-oil emulsion, an oil-in-water-in-oil emulsion, and a water-in-oil-in water emulsion.

6. (Original) The composition of claim 1 wherein said emulsion is a microemulsion.

7. (Previously presented) The composition of claim 6 wherein said microemulsion is selected from the group consisting of an oil-in-water microemulsion, a water-in-oil microemulsion, an oil-in-water-in-oil microemulsion, and a water-in-oil-in water microemulsion.

8-11. (Cancelled).

12. (Original) The composition of claim 1 wherein said bile salt is selected from the group consisting of cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, sodium tauro-24,25-dihydrofusidate, sodium glycodihydrofusidate, polyoxyethylene-9-lauryl ether and a pharmaceutically acceptable salt thereof.

13. (Currently amended) The composition of claim 1 ~~wherein said penetration enhancer is a combination of~~ further comprising at least one fatty acid ~~and at least one bile salt~~.

14-18. (Cancelled).

19. (Original) The composition of claim 1 further comprising at least one carrier compound.

20. (Previously presented) The composition of claim 19 wherein said carrier compound is selected from the group consisting of polyinosinic acid, dextran sulfate, polycytidic acid, and 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid.

21-79. (Cancelled).

80. (Previously presented) The composition according to claim 1, wherein said oligonucleotide is SEQ ID NO:1.

81-83. (Cancelled).

84. (previously presented) The composition of claim 1 wherein said emulsion is an oil-in-water-in-oil emulsion or a water-in-oil-in-water emulsion.

85. (previously presented) The composition according to claim 1, wherein said oligonucleotide is selected from the group consisting of SEQ ID NOS: 2, 48, 49, 50, 16, 19, 51, 52, 53, and 54.

86. (Cancelled).

87. (Not entered)

88. (Cancelled).

89. (Not entered)

90. (Cancelled)

91. (Previously presented) The composition of claim 87 in dosage form suitable for non-parenteral administration.

92. (Previously presented) The composition of claim 87 in oral dosage form.

93. (Cancelled).

94. (Not entered)

95. (Previously presented) The composition of claim 1 in oral dosage form.

96. (Cancelled).